Neuronal progenitors have the potential to revolutionize neuronal drug discovery, and treatment of neurodegenerative diseases such as spinal cord injury, Parkinson’s, Alzheimer’s, and many more
Irvine, CA (PRWEB) June 07, 2011
California Stem Cell announced today that the manuscript, “Derivation of High Purity Neuronal Progenitors from Human Embryonic Stem Cells,”has been accepted by PLos ONE for publication. The manuscript and research was prepared in conjunction with the University of California at Irvine and Pfizer Corporation.
Hans Keirstead, PhD, UC Irvine Professor of Anatomy and Neurobiology and Neurosurgery at the Reeve-Irvine Research Center, and Chairman of the Scientific Advisory Board of California Stem Cell (CSC) advised the team that came up with the innovative treatment. Said Keirstead, “This method of deriving neuronal progenitors from embryonic stem cells offers a safe, highly scalable and efficient process for both therapeutic and commercial use. Neuronal progenitors have the potential to revolutionize neuronal drug discovery, and treatment of neurodegenerative diseases such as spinal cord injury, Parkinson’s, Alzheimer’s, and many more.”
The availability of human neuronal progenitors (hNPs) in high purity would greatly facilitate neuronal drug discovery and developmental studies, as well as cell replacement strategies for neurodegenerative diseases and conditions, such as spinal cord injury, stroke, Parkinson’s disease, Alzheimer’s disease, and Huntington’s disease. Here we describe for the first time a method for producing hNPs in large quantity and high purity from human embryonic stem cells (hESCs) in feeder-free conditions, without the use of exogenous noggin, sonic hedgehog or analogs, rendering the process clinically compliant. The resulting population displays characteristic neuronal-specific markers. When allowed to spontaneously differentiate into neuronal subtypes in vitro, cholinergic, serotonergic, dopaminergic and/or noradrenergic, and medium spiny striatal neurons were observed. When transplanted into the injured spinal cord the hNPs survived, integrated into host tissue, and matured into a variety of neuronal subtypes. Our method of deriving neuronal progenitors from hESCs renders the process amenable to therapeutic and commercial use.
PLoS ONE is a peer-reviewed, international, open-access journal publishing important original research and analysis relevant to human health.
ABOUT CALIFORNIA STEM CELL
Founded in 2005, California Stem Cell is to catalyze the efficient development of human therapies based on human embryonic stem cells. CSC has developed proprietary methods for scalable production of human motor neurons, neuronal progenitors, hepatocytes, and cardiac cells, at high purity, from hESCs.
CSC is currently developing stem cell based therapies for spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS, or Lou Gehrig's Disease). CSC also markets high-purity human cells in platforms suitable for high throughput and high content screening of conventional drug candidates using human cell substrates, predictive toxicity of conventional drugs using human cell substrates, and development of experimental research tools. CSC is a privately held Delaware Corporation with headquarters and research facilities in Irvine, CA.
CSC can economically supply large quantities of high purity cells for our own clinical development pipeline in specific application areas. CSC can also supply high purity, fully characterized, clinically relevant human cell populations to companies or other institutions for development of therapies, efficacy screening or creation of toxicity profiles for candidate drugs, or experimental research.
Find us on Facebook: http://www.facebook.com/csc
Follow us on Twitter: http://twitter.com/castemcell